ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
BLV
Projektnummer
1.15.03
Projekttitel
KILLeuPRRSV Control of highly virulent/pathogenic European porcine reproductive and respiratory syndrome viruses
Projekttitel Englisch
Control of highly virulent/pathogenic European porcine reproductive and respiratory syndrome viruses

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Kurzbeschreibung
-
-
-
Anzeigen
Projektziele
-
-
-
Anzeigen

Erfasste Texte


KategorieText
Kurzbeschreibung
(Englisch)
In the present project proposal, the ANIHWA consortium KILLeuPRRSV proposes to analyse the pathogenesis of highly virulent/pathogenic European PRRSV (genotype 1) subtype I (prototype Flanders13) & subtype III (prototype Lena) strains, to determine the cell type that is infected and to identify the receptor used, which then can be used to delineate virus neutralization strategies (WP1). We will also investigate cell intrinsic factors regulating virus replication. We further propose to examine the effect of infection by these European PRRSV strains on the functionality of monocytic cells (WP2). Because we previously identified that inactivated vaccines may cause an immunity-dependent enhancement of replication and disease, the mechanism will be examined with the aim to propose an improved strategy to make fully safe inactivated vaccines (WP3). In WP4 and WP5, the efficacy of already developed vaccine candidates including RNA replicon vaccines selected for potent T-cell stimulatory capacity  will be tested against the highly virulent European PRRSV subtype I/III strains. In WP6, a horizon scanning network will be established to enable the real time detection of circulating highly virulent PRRSV strains in Europe.
Projektziele
(Englisch)
The general aim of the project proposal is to better control PRRS in Europe, with special attention to emerging highly virulent/pathogenic European (type I) PRRSV strains. More specifically, it is aimed to (1) have a better understanding of the current epidemiological situation of these strains, (2) unravel their pathogenesis (monocytic cell tropism, immune-suppression) (3) produce safe and efficacious adaptable vaccines against these strains.